Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2025)

Bicycle Therapeutics' Free Cash Flow history spans 8 years, with the latest figure at -$19.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 104.01% year-over-year to -$19.9 million; the TTM value through Dec 2025 reached -$252.0 million, down 51.86%, while the annual FY2025 figure was -$252.0 million, 51.86% down from the prior year.
  • Free Cash Flow reached -$19.9 million in Q4 2025 per BCYC's latest filing, up from -$71.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $33.8 million in Q2 2023 to a low of -$87.0 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$30.2 million, with a median of -$31.5 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: surged 313.78% in 2021, then tumbled 2537.0% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$11.5 million in 2021, then plummeted by 176.1% to -$31.8 million in 2022, then plummeted by 49.07% to -$47.3 million in 2023, then soared by 79.37% to -$9.8 million in 2024, then tumbled by 104.01% to -$19.9 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Free Cash Flow are -$19.9 million (Q4 2025), -$71.8 million (Q3 2025), and -$73.3 million (Q2 2025).